Littérature scientifique sur le sujet « Repurposed drug »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Repurposed drug ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Repurposed drug"
Al Khzem, Abdulaziz H., Mohamed S. Gomaa, Mansour S. Alturki, Nada Tawfeeq, Mohammad Sarafroz, Shareefa M. Alonaizi, Alhassan Al Faran, Laela Ahmed Alrumaihi, Fatimah Ahmed Alansari et Abdullah Abbas Alghamdi. « Drug Repurposing for Cancer Treatment : A Comprehensive Review ». International Journal of Molecular Sciences 25, no 22 (19 novembre 2024) : 12441. http://dx.doi.org/10.3390/ijms252212441.
Texte intégralAleksic, Sandra. « REPURPOSED FOR AGING ». Innovation in Aging 8, Supplement_1 (décembre 2024) : 139–40. https://doi.org/10.1093/geroni/igae098.0449.
Texte intégralAraújo, Diana, Eduarda Ribeiro, Irina Amorim et Nuno Vale. « Repurposed Drugs in Gastric Cancer ». Molecules 28, no 1 (30 décembre 2022) : 319. http://dx.doi.org/10.3390/molecules28010319.
Texte intégralOlgen, Sureyya, et Lakshmi P. Kotra. « Drug Repurposing in the Development of Anticancer Agents ». Current Medicinal Chemistry 26, no 28 (25 octobre 2019) : 5410–27. http://dx.doi.org/10.2174/0929867325666180713155702.
Texte intégralMoura, Catarina, Ana Salomé Correia, Mariana Pereira, Eduarda Ribeiro, Joana Santos et Nuno Vale. « Atorvastatin and Nitrofurantoin Repurposed in the Context of Breast Cancer and Neuroblastoma Cells ». Biomedicines 11, no 3 (15 mars 2023) : 903. http://dx.doi.org/10.3390/biomedicines11030903.
Texte intégralProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti et Roberto Gambari. « A Rational Approach to Drug Repositioning in β-thalassemia : Induction of Fetal Hemoglobin by Established Drugs ». Wellcome Open Research 7 (23 juin 2022) : 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.2.
Texte intégralProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti et Roberto Gambari. « A Rational Approach to Drug Repositioning in β-thalassemia : Induction of Fetal Hemoglobin by Established Drugs ». Wellcome Open Research 7 (17 août 2022) : 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.3.
Texte intégralProsdocimi, Marco, Cristina Zuccato, Lucia Carmela Cosenza, Monica Borgatti, Ilaria Lampronti, Alessia Finotti et Roberto Gambari. « A Rational Approach to Drug Repositioning in β-thalassemia : Induction of Fetal Hemoglobin by Established Drugs ». Wellcome Open Research 7 (12 mai 2022) : 150. http://dx.doi.org/10.12688/wellcomeopenres.17845.1.
Texte intégralStone, Heather, Mili Duggal, Leonard Sacks et Mayurika Ghosh. « 1380. Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis : An Analysis of Adverse Events Reported in the Literature ». Open Forum Infectious Diseases 6, Supplement_2 (octobre 2019) : S501. http://dx.doi.org/10.1093/ofid/ofz360.1244.
Texte intégralJayaram, Saravanan, Emdormi Rymbai, Deepa Sugumar et Divakar Selvaraj. « Drug Repurposing : A Paradigm Shift in Drug Discovery ». INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH 5, no 04 (30 juin 2020) : 60–68. http://dx.doi.org/10.21477/ijapsr.5.4.2.
Texte intégralThèses sur le sujet "Repurposed drug"
Olayanju, Olatunde. « Efficacy and safety of novel and repurposed drugs for the treatment of drug-resistant tuberculosis ». Doctoral thesis, Faculty of Health Sciences, 2020. http://hdl.handle.net/11427/32322.
Texte intégralHervieu, Laura. « Dévelοppement et évaluatiοn de nanοvecteurs pοur l'administratiοn οrale de fénοldοpam en vue du traitement de la pοlykystοse rénale autοsοmique dοminante ». Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMR100.
Texte intégralAutosomal dominant polycystic kidney disease (ADPKD) is a hereditary disorder characterized by the presence of cysts in the kidneys and associated cardiovascular complications. It is responsible for about 5 to 10% of end-stage renal failure cases. Currently, there is no treatment available for the therapeutic management of renal and cardiovascular complications of ADPKD. The disease is characterized by dysfunction of polycystins in the cilia of vascular endothelial and renal tubular cells, which play a role in detecting mechanical stimuli. Numerous studies have highlighted the therapeutic potential of stimulating dopamine type 5 receptors (D5), which can restore the mechanosensitivity of endothelial cells. Among dopamine agonists, fenoldopam stands out due to its selectivity for D5 receptors. However, its physicochemical properties, particularly its short half-life and sensitivity to metabolism, make it poorly suited for oral administration, a preferred route for chronic diseases. In this context, fenoldopam has been formulated into nanoemulsions and liposomes. Both formulations allowed for the encapsulation of fenoldopam. While the nanoemulsions showed instability in biomimetic media, confirmed by the lack of improvement in the pharmacokinetic profile, the liposomes demonstrated greater stability. They also modified the fate of fenoldopam compared to its free form in solution after oral administration, suggesting the possibility of achieving prolonged release
Hou, Chun-Li, et 侯君里. « The pan-Aurora kinase inhibitor tozasertib as a repurposed drug for Mycn-amplified neuroblastoma ». Thesis, 2016. http://ndltd.ncl.edu.tw/handle/91763913618808780304.
Texte intégralChung, Feng-Hsiang, et 鍾豐翔. « A Framework for Searching for Repurposed Drug Compounds for Systems Treatment of Complex Diseases : An Application to Colorectal Adenocarcinoma ». Thesis, 2014. http://ndltd.ncl.edu.tw/handle/8249tv.
Texte intégral國立中央大學
系統生物與生物資訊研究所
102
Drug repurposing has become an increasingly attractive approach to drug development owing to the ever-growing cost of new drug discovery and frequent withdrawal of successful drugs caused by side effect issues. Cancer is now recognized as is a systems disease caused by the breakdown of a large part of the cellular system, not just of the failure of one or two genes. Therefore, one cannot expect cancer to be effectively treated by one or a few single-target drugs. Here, we devised Functional Module Connectivity Map (FMCM) for the discovery of repurposed drug compounds for systems treatment of complex diseases, and applied it to colorectal adenocarcinoma. FMCM used multiple functional gene modules to query the Connectivity Map (CMap). The functional modules were built around hub genes identified, through the Gene Selection by Trend-of-disease-Progression (GSToP) procedure, from condition-specific gene-gene interaction networks constructed from sets of cohort gene expression microarrays. The formulated drug compounds were restricted to drugs exhibiting predicted minimal intracellular harmful side effects. Genes selected by GSToP had a much higher cancer gene hit rate (~50%) than that obtained by eBayes and SAM (~20%). We tested FMCM against the common practice of selecting drugs by using a single set of individual genes to query CMap (IGCM), and found that FMCM have higher robustness, accuracy, and reproducibility in identifying known anti-cancer agents. Among the 46 drugs selected by FMCM for colorectal adenocarcinoma, 65% had literature support for association with anti-cancer activities, and three drugs predicted to have adverse harmful effects on cancers had also been reported. In cell viability tests, we validated four candidate drugs: GW-8510, etacrynic acid, ginkgolide A, and 6-azathymine, as having high inhibitory activities against cancer cells. Through microarray experiments we confirmed the novel functional links predicted for three candidate drugs: phenoxybenzamine (broad effects), GW-8510 (cell cycle), and imipenem (immune system). We expect FMCM can be widely applied to repurposed drug discovery for systems treatment of other complex diseases.
Pacheco, Mariana Carvalho Dias Brutt. « Demethylation of the epigenetically silenced androgen receptor gene by a repurposed drug in castration-resistant prostate cancer cell lines ». Master's thesis, 2019. https://hdl.handle.net/10216/124744.
Texte intégralPacheco, Mariana Carvalho Dias Brutt. « Demethylation of the epigenetically silenced androgen receptor gene by a repurposed drug in castration-resistant prostate cancer cell lines ». Dissertação, 2019. https://hdl.handle.net/10216/124744.
Texte intégralStylianou, Marios. « Pharmaceutical And Immunollogical Challenge Of Fungal Pathogens ». Doctoral thesis, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-107713.
Texte intégralLivres sur le sujet "Repurposed drug"
Starving Cancer and Viruses with Commonly-Prescribed Pills : The Repurposed Drug Revolution. hope pressworks international, 2020.
Trouver le texte intégralRepurposed Drugs for Cancer [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.91884.
Texte intégralSingh, Pankaj Kumar, Dharmendra Kumar Khatri, Shashi Bala Singh et Anitha Sriram, dir. An Update on SARS-CoV-2 : Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy Volume 1. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150398631220101.
Texte intégralParihar, Suraj P., Shashank Gupta, Makram Essafi, Bibhuti Mishra et Ramandeep Singh, dir. Repurposed Drugs as Immune- Modulators to Combat Infectious Diseases. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-370-4.
Texte intégralCampos-Parra, Alma D., Carlos Pérez-Plasencia, Teresita Padilla-Benavides et Eduardo López-Urrutia, dir. Repurposed Drugs Targeting Cancer Signaling Pathways : Clinical Insights to Improve Oncologic Therapies. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-239-7.
Texte intégralHwang, Young-Hwan, et York Pei. Autosomal dominant polycystic kidney disease management. Sous la direction de Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0309_update_001.
Texte intégralCampos-Parra, Alma D., Carlos Pérez-Plasencia, Teresita Padilla-Benavides et Eduardo López-Urrutia, dir. Repurposed Drugs Targeting Cancer Signaling Pathways : Dissecting New Mechanisms of Action Through in vitro and in vivo Analyses. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-716-3.
Texte intégralHudson, Dale. Terrorist Vampires : Religious Heritage or Planetary Advocacy. Edinburgh University Press, 2018. http://dx.doi.org/10.3366/edinburgh/9781474423083.003.0007.
Texte intégralChapitres de livres sur le sujet "Repurposed drug"
Patil, Ruchira, Harshad Takate, Gaurav Shanbhag, Harshada Kiran Sonawane, Amruta Prabhakar Padakanti et Naveen Chella. « Clinical Trials on Repurposed Drugs : An Overview ». Dans Drug Repurposing, 173–99. Singapore : Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-5016-0_9.
Texte intégralReaume, Andrew G., et Christopher A. Lipinski. « Chapter 10. Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy ». Dans Drug Repurposing, 196–220. Cambridge : Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839163401-00196.
Texte intégralChopra, Simran, Aditya Dahiya, Ashrit Nair, Navneet Sharma et Rakesh Kumar Sharma. « 2-Deoxy-d-Glucose : A Repurposed Drug for COVID-19 Treatment ». Dans Drug Repurposing for Emerging Infectious Diseases and Cancer, 479–500. Singapore : Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_20.
Texte intégralDahiya, Mini, Anil Kumar, Monu Yadav, Pratibha Dhakla et Shiva Tushir. « Therapeutic Targeting of Antineoplastic Drugs in Alzheimer’s Disease : Discovered in Repurposed Agents ». Dans Drug Repurposing for Emerging Infectious Diseases and Cancer, 329–45. Singapore : Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5399-6_15.
Texte intégralGautam, Rupesh K., Ritu Mishra, Kanika Sharma et Manju Sharma. « Cellular and Molecular Mechanisms of Repurposed Antidiabetic Drug as an Adjunctive Treatment for Tuberculosis ». Dans Targeting Cellular Signalling Pathways in Lung Diseases, 355–72. Singapore : Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-6827-9_15.
Texte intégralCervantes, Duilio, et Aida Adlimoghaddam. « Repurposed Drugs ». Dans Small Molecules in Neurodegeneration, 137–50. Boca Raton : CRC Press, 2025. https://doi.org/10.1201/9781003520610-8.
Texte intégralArrowsmith, John, et Richard Harrison. « Drug Repositioning : The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs ». Dans Drug Repositioning, 7–32. Hoboken, NJ, USA : John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118274408.ch1.
Texte intégralMorasso, Stefano, Elisa Costanzi, Nicola Demitri, Barbara Giabbai et Paola Storici. « The Role of Structural Biology Task Force : Validation of the Binding Mode of Repurposed Drugs Against SARS-CoV-2 Protein Targets ». Dans Exscalate4CoV, 51–59. Cham : Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-30691-4_7.
Texte intégralDhir, Neha, Ashish Jain, Dhruv Mahendru, Ajay Prakash et Bikash Medhi. « Drug Repurposing and Orphan Disease Therapeutics ». Dans Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.91941.
Texte intégralT. Galatage, Sunil, Arehalli S. Manjappa, Raghwendra R. Waghmode, Swapnil S. Harale, Rushikesh B. Katkar, Sujit A. Desai, Swapnil S. Chopade et al. « Role of Drug Repurposing in Cancer Treatment and Liposomal Approach of Drug Targeting ». Dans Drug Repurposing - Advances, Scopes and Opportunities in Drug Discovery [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.110105.
Texte intégralActes de conférences sur le sujet "Repurposed drug"
Ding, Yi, Ruiyang Gong, Juzhen Bai, Ruizhi Ou et Zimeng Wu. « CTAG using GNN for GWAS analyses of schizophrenia to identify disease-associated genes and repurpose drugs ». Dans 2024 Fourth International Conference on Biomedicine and Bioinformatics Engineering (ICBBE 2024), sous la direction de Pier Paolo Piccaluga, Ahmed El-Hashash et Xiangqian Guo, 21. SPIE, 2024. http://dx.doi.org/10.1117/12.3044175.
Texte intégralCavalla, David. « Commercialising drug repurposed products : what works and what doesn’t ». Dans RExPO24. REPO4EU, 2024. http://dx.doi.org/10.58647/rexpo.24010.
Texte intégralEvankovich, J., J. Villandre, T. Lear, Y. Chen, F. Tuncer, V. White, D. Camarco, Y. Liu et B. Chen. « A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells ». Dans American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4388.
Texte intégralEvankovich, J., J. Villandre, V. White, T. Lear, Y. Chen, F. Tuncer, K. Lockwood, D. Camarco, Y. Liu et B. Chen. « A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells ». Dans American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3254.
Texte intégralYadav, Anjali, Shraddha Bhutkar et Vikas Dukhande. « Metabolic Rewiring and Mechanism of Action of an Antiepileptic Drug Repurposed for its Potential in Glioblastoma ». Dans ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.291070.
Texte intégralRabbani, Naila, Paul John Thornalley, Maryam Al-Motawa et Mingzhan Xue. « Vulnerabilities of the SARS-Cov-2 Virus to Proteotoxicity – Opportunity for Repurposed Chemotherapy of COVID-19 Infection ». Dans Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0291.
Texte intégralPapineni, Rao V., Shahid Umar, Alexey Goltsov et Ishfaq Ahmed. « Abstract LB-012 : Deoxyglucose and bisphosphonate shows common pathways in its drug repurposed anticancer and anti-infection actions ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-lb-012.
Texte intégralFahal, AH, ES Ahmed, SM Bakhiet, OE Bakheet, LA Fahal, AA Mohamed, ESW Mohhamedelamin et al. « Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan : a randomised, double-blind, phase 2, proof-of-concept superiority trial ». Dans MSF Scientific Days International 2024. NYC : MSF-USA, 2024. http://dx.doi.org/10.57740/jznxuiaji7.
Texte intégralChakravarti, Sayak, Suman Mazumder, Farnaz Hemmati, Farshad Amiri, Taraswi Mitra Ghosh, Ujjal Kumar Mukherjee, Panagiotis Mistriotis et al. « Abstract 1354 : Deciphering the functional basis of synergy between taxanes and TAK715 : A novel repurposed drug candidate in treatment-refractory aggressive prostate cancer ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1354.
Texte intégralNeal, Tristan, Nanyun Tang, George Reid, Sara Byron, Harshil Dhruv et Michael Berens. « Abstract 2189 : Evaluating efficacy of repurposed drugs in treatment of glioblastoma ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2189.
Texte intégral